MCAS Protocol Stack
IMMUNITYQuick Specifications
| Vial Size | SOLD AS 4-PART IMMUNE PROTOCOL |
|---|---|
| BAC Water | SEE INDIVIDUAL PEPTIDE ENTRIES |
| Amount Per Unit | SEE INDIVIDUAL ENTRIES |
| Recommended Dose | SEE INDIVIDUAL PEPTIDE ENTRIES FOR PRECISE DOSING |
| Frequency | VIP DAILY INTRANASAL; ARA-290 DAILY SUBCUTANEOUS; KPV DAILY SUBCUTANEOUS; TA-1 2X PER WEEK SUBCUTANEOUS |
| Injection Type | INTRANASAL (VIP) + SUBCUTANEOUS (ARA-290, KPV, TA-1) |
| Timing | Week 1: Begin VIP alone, titrating from 50mcg intranasal twice daily — establish mast cell stabilization baseline before adding other components. Week 2+: Add ARA-290 100-200mcg SubQ morning and KPV 200-500mcg SubQ daily. Week 3+: Add TA-1 1.5mg SubQ twice weekly. This staged introduction allows identification of individual compound tolerability. See individual entries (VIP, KPV, TA-1) for full reconstitution and dosing. Ongoing monitoring of symptom load recommended throughout. |
Research Overview
The MCAS Protocol Stack combines four immune-modulating peptides that address mast cell activation syndrome (MCAS) and CIRS (chronic inflammatory response syndrome) through four distinct, non-overlapping mechanisms. VIP (Vasoactive Intestinal Peptide) acts as the primary mast cell degranulation suppressor — binding VPAC1/VPAC2 receptors on mast cells and immune cells to reduce histamine release, reduce pro-inflammatory cytokines (IL-6, TNF-alpha) by up to 40%, and modulate the mast cell response without broadly suppressing immune function. VIP also synchronizes the suprachiasmatic nucleus for circadian rhythm regulation relevant to immune cycling. ARA-290 (Cibinetide) adds neuroprotective and tissue-repair signaling via the innate repair receptor (IRR) — particularly relevant for the small fiber neuropathy (SFN) that is commonly comorbid with MCAS, addressing the neurological component of mast cell-driven tissue damage. KPV (melanocortin tripeptide from alpha-MSH) provides targeted mucosal anti-inflammatory signaling via MC1R and MC3R, reducing gut and skin inflammation driven by mast cell degranulation products. TA-1 (Thymosin Alpha-1) normalizes T-regulatory (Treg) cell populations — restoring the immune calibration that prevents the hyperactive immune responses driving MCAS chronicity. The four mechanisms collectively address mast cell activity (VIP), neuroprotection (ARA-290), mucosal anti-inflammation (KPV), and T-regulatory normalization (TA-1) — the most complete peptide-based MCAS research protocol available. For research and educational purposes only. Consult a qualified healthcare professional.
Commonly Studied With
These peptides are frequently researched alongside MCAS Protocol Stack: VIP (10mg) / ARA-290 (2mg) / KPV (10mg) / TA-1 (5mg) due to complementary mechanisms:
For research-grade the MCAS Protocol Stack with third-party Certificate of Analysis documentation, Peptide Hub recommends Apollo Peptide Sciences. Apollo Peptide Sciences carries VIP, LL-37, KPV, and TA-1 for the MCAS Protocol Stack. Affiliate disclosure: we may earn a commission on purchases through this link.
MCAS Protocol Stack: VIP (10mg) / ARA-290 (2mg) / KPV (10mg) / TA-1 (5mg) information on this page is for research and educational purposes only. This content is not FDA-approved, does not constitute medical advice, and should not be used to guide personal health decisions. Consult a qualified healthcare professional before using any research compound.
Dose Calculator
Enter your target dose to calculate the volume to draw.
Recommended dose: SEE INDIVIDUAL PEPTIDE ENTRIES FOR PRECISE DOSING